FDA cracks down on tianeptine claimsThe Food and Drug Administration last week issued warning letters to two companies that the agency said were illegally marketing products containing tianeptine as dietary supplements — a move that the Council for Responsible Nutrition applauded. Lupin launches generic XenazineLupin is introducing generic Xenazine tablets, which had a market value of $153 million. Pfizer gets FDA green light for Daurismo The FDA's approval of Pfizer's Daurismo provides a treatment for adults age 75 years old or older with acute myeloid leukemia. MinuteClinic gets Joint Commission’s Gold Seal of Approval for ambulatory care CVS Health's MinuteClinic has received its fifth consecutive accreditation from The Joint Commission. Glenmark gets FDA nod for generic Finacea gel Glenmark has received the FDA's blessing for generic Finacea gel, which had a market value of about $64.1 million. FDA approves Gamifant for ultra-rare illness Sobi and Novimmune will bring Gamifan to patients with HLH, an ultra-rare syndrome of hyper-inflammation. Aries gets FDA green light for Aemcolo Aries' Aemcolo (rifamycin) is the first antibiotic approved for travelers' diarrhea in over a decade. Indivior gets FDA nod for Perseris Indivior’s once-monthly Perseris now offers a new option for treating adults with schizophrenia. Hikma unveils generic Halcion Hikma is introducing generic Halcion, which had a market value of about $27 million for the year ended September 2018, according to IQVIA data. FDA clears new indication for Promacta The FDA's approval for a new indication for Promacta provides a new treatment for a rare life-threatening disease. First Previous 32 33 34 35 36 Next Last
